News and Press Releases

Contact Veristat Now


Request A Proposal

Contact Us

Veristat Supports Antibe Therapeutics for Pain and Inflammation Study

November 7, 2018

Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346.   The study will run in Canada and is expected to conclude in December 2018.

Read More

Veristat Partners with TRI For Risk-Based Monitoring Technology

November 5, 2018

Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients

 

Read More

Veristat Strengthens Clinical Operations Capabilities - Acquires Topstone Research

October 1, 2018

Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma

Read More